See more : Oppein Home Group Inc. (603833.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- AEON Credit Service (M) Berhad (5139.KL) Income Statement Analysis – Financial Results
- Mowi ASA (MHGVY) Income Statement Analysis – Financial Results
- Kazan Public Joint Stock Company Organichesky sintez (KZOSP.ME) Income Statement Analysis – Financial Results
- SHINSEGAE FOOD Inc. (031440.KS) Income Statement Analysis – Financial Results
- Trajectory Alpha Acquisition Corp. (TCOA) Income Statement Analysis – Financial Results
Provention Bio, Inc. (PRVB)
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 12.90M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 512.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.38M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.03% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.80M | 69.63M | 66.36M | 36.36M | 22.65M | 7.68M |
| General & Administrative | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Other Expenses | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 140.54M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Cost & Expenses | 141.06M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Interest Income | 2.24M | 146.00K | 583.00K | 1.09M | 669.00K | 131.50K |
| Interest Expense | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.47M | 387.00K | 33.00K | -16.00K | 149.00K | 6.50K |
| EBITDA | -124.69M | -115.58M | -99.69M | -44.37M | -26.67M | -9.13M |
| EBITDA Ratio | -966.98% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -128.16M | -115.58M | -99.69M | -44.37M | -26.81M | -9.14M |
| Operating Income Ratio | -993.88% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.20M | 146.00K | 583.00K | 1.09M | 149.00K | 6.50K |
| Income Before Tax | -126.96M | -115.43M | -99.10M | -43.29M | -26.67M | -9.13M |
| Income Before Tax Ratio | -984.54% | -8,274.70% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -13.39M | -1.00M | -523.00K | -1.09M | -187.00K | -131.50K |
| Net Income | -113.57M | -114.43M | -98.58M | -42.20M | -26.48M | -9.13M |
| Net Income Ratio | -880.69% | -8,203.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| Weighted Avg Shares Out | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
| Weighted Avg Shares Out (Dil) | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
Sanofi to buy Provention Bio in deal worth $2.9 billion
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Provention Bio Announces the Grant of Inducement Awards
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
Source: https://incomestatements.info
Category: Stock Reports